2024 Drug Pricing Pharmaceutical Companies 
STAT
OCTOBER 21, 2024
WASHINGTON — Most executives at pharmaceutical companies haven’t directly donated to political candidates over the final stretch of the 2024 campaign. 30, five gave to Democratic candidates, even though Democratic lawmakers passed the most aggressive drug pricing reform in decades in 2022.
STAT
MARCH 18, 2024
The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies. Continue to STAT+ to read the full story…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
NOVEMBER 28, 2024
Organisation of Pharmaceutical Producers of India (OPPI) in partnership with BCG has released a new report, titled “Winning in Indian Healthcare”. Global pharmaceutical companies have played a pivotal role in transforming the healthcare sector in India.
STAT
OCTOBER 18, 2024
As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You
Express Pharma
FEBRUARY 7, 2025
The Indian pharmaceuticals market (IPM) is projected to grow by 8 per cent year-on-year in FY26, supported by a 4 per cent-5 per cent increase in drug prices, volume growth, and new product launches. Most large pharmaceutical companies rated by Ind-Ra fall into high investment-grade categories.
Drug Channels
FEBRUARY 7, 2024
And contrary to what you might read, drug spending growth was *not* driven by purportedly “skyrocketing” drug prices. In reality, nearly all drug spending growth occurred due to growth in the number of people treated, prescriptions dispensed, and other nonprice factors. healthcare expenditures. healthcare expenditures.
Pharmaceutical Technology
JANUARY 16, 2023
This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. Free Report.
Expert insights. Personalized for you.
363 
Let's personalize your content